16 June 2022
BerGenBio ASA: BerGenBio – Mandatory notification of trade by Primary Insider
Bergen, Norway,16 June 2022 -BerGenBioASA (OSE: BGBIO) (the “Company”), has been notified that Anders Tullgren, Chairman of the Board and primary insider of BerGenBio ASA, has bought 25,000 shares in BerGenBio ASA at an average price of NOK 10.73 per share. The shares are purchased under the sign on bonus agreement approved by the Extraordinary General Meeting 6 January 2022 in connection with the appointment of Mr. Tullgren as Chairman of the Board in BerGenBio ASA.
After the transaction Mr. Tullgren holds 50,000 shares in BerGenBio ASA.
Please see the attached document for further details of the transaction.
Contact:
Martin Olin, CEO,BerGenBioASA
ir@bergenbio.com
RuneSkeie, CFO,BerGenBioASA
rune.skeie@bergenbio.com
This information issubject to the disclosure requirements pursuant to the EU Market Abuse Regulation (MAR) and section 5-12 of the Norwegian Securities Trading Act.
About Oncoinvent
Oncoinvent is developing Radspherin®, a receptor-independent alpha radiation therapy that leverages the unique anatomy of the abdominal cavity to destroy residual micrometastases using a single, highly localized dose of alpha radiation. The initial clinical focus is treatment of ovarian and colorectal cancer patients after surgical removal of the primary tumor and visible metastases in the peritoneum, the thin membrane lining the abdominal cavity and covering the abdominal organs.
This radiopharmaceutical is designed to prevent or delay recurrence in the peritoneal cavity, keeping patients disease-free for longer than the current standard of care and thereby also impacting overall survival. It is broadly applicable to any cancer that spreads to the peritoneum, e.g. ovarian, colorectal, and gastric cancers. Radspherin® stands out for its simplicity, excellent safety profile, and seamless integration into existing surgical workflows. Oncoinvent’s product is easy to use, avoids systemic delivery and significant toxicity. It is also differentiated in being simple to manufacture, scalable, and supply de-risked.
Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers, are highly promising, showing an excellent safety profile and meaningful signals of efficacy. Interim data from an ongoing, randomized, controlled phase 2 ovarian cancer trial is expected in 2026. With cost-effective manufacturing, blockbuster potential, active pharma partnership momentum, plus strong endorsements from leading experts, Oncoinvent is built for scale and commercial success, and is set to become the new standard for post-surgical cancer care. The Company was founded by the originators of Algeta and Xofigo (acquired by Bayer).
